Investigation conclusion: retention products were tested with hcg quality control cut-off standard (25 miu/ml) and high level hcg clinical urine (212.6 iu/ml, 215.2 iu/ml, 203.5 iu/ml).All devices showed positive results at read time and met quality control release specifications.No false negative results were obtained during in-house testing.Manufacturing batch record review did not uncover any abnormalities.Case details do not indicate if the urine sample was a first morning catch.Per the package insert, very dilute urine may not contain representative levels of hcg.This test provides a presumptive diagnosis for pregnancy.A confirmed pregnancy diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.Based on the information available, there is no indication of a product deficiency and no corrective action is required.
|
The patient's last menstrual period was 2-3 weeks prior to (b)(6) 2018.On (b)(6) 2018, a urine sample was collected and a hcg one step pregnancy test device produced a negative hcg result (urinalysis: glu -ve, ket 15, sg 1.020, blo large, pro trace, nit -ve, leu -ve).A beta hcg quantitative blood test was performed the same day and produced a result of 127 miu/ml with a progesterone of 9 (no units provided).The pregnancy was determined to be non-viable.However, the customer also stated that the patient was on a medication that may have been potentially harmful to a viable pregnancy.On (b)(6) 2018, a repeat beta hcg quantitative blood test was performed and produced a result of 95 miu/ml.On (b)(6), 2018, a third beta hcg quantitative blood test was performed and produced a result of 91 miu/ml.The patient outcome was a miscarriage and the patient was later discharged.
|